Tria Beauty wins lawsuit against rival Oregon Aesthetics

Tria Beauty Inc. won a legal battle against Oregon Aesthetic Technologies Inc. over a device that uses light to treat acne.

Dublin-based Tria had sued Oregon Aesthetic Technologies over a "blue light acne treatment device," saying it was falsely advertised as having been clinically tested and approved by regulators. Tria sells its own blue light acne treatment which has been tested and cleared by the Food and Drug Administration.

Tria Beauty prices IPO at $13-$15

Tria Beauty Inc. is getting an IPO haircut. The Dublin-based aesthetic device company priced its initial public offering at $13 to $15 per share, raising $59.8 million to $69 million from the sale of 4.6 million shares. In January, when it filed for its IPO, it said it would raise up to $86 million. Tria makes in-home cosmetic devices that use light to remove hair, fight acne and treat other skin conditions. It will seek approval later this year for a skin-rejuvenating laser to treat "crow's feet," wrinkles around the mouth, uneven pigmentation and rough skin.

Tria Beauty files to raise up to $86M IPO

Tria Beauty Inc. registered with regulators Monday for an initial public offering worth up to $86.25 million.
Pleasanton-based Tria Beauty makes cosmetic devices that use light to treat the skin. They’re meant for consumers to buy and use at home, rather than at a medical office.
Tria’s devices include a hair removal laser that was cleared by the Food and Drug Administration in 2005 for prescription use and then in 2008 for over-the-counter sales. The company also got FDA clearance in 2010 for over-the-counter sales of a blue light device meant to reduce acne.